Smart Science for Serious Disease

PsiOxus aims to be the world’s leading immuno-oncolytic virus company, delivering medicines of value to patients with cancer.

Our work is product and platform based with a focus on discovering and developing innovative immunotherapies for the treatment of solid tumors. Our products utilize enadenotucirev, our proprietary first generation oncolytic virus and our proprietary platform technology for next generation oncolytic viruses, Tumor-Specific Immuno-Gene Therapy (T-SIGn).

Our world leading scientists and highly experienced management team are based in Oxford, UK and Philadelphia, USA.

Enadenotucirev

An optimised oncolytic virus

T-SIGn

Tumour-Specific Immuno-Gene Therapy Platform

NG-348

The first next generation T-SIGn virus

NG-347

More info available soon

NG-350-A

More info available soon

NG-600

More info available soon

Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image
Menu